The Court of Appeals (CA) has denied Sanofi Pasteur’s motion for reconsideration regarding its Dengvaxia dengue vaccine, upholding a previous decision that revoked the vaccine’s certificates of product registration (CPRs) in 2018.
The revocation followed Sanofi’s 2017 disclosure that Dengvaxia posed risks to individuals who had not previously contracted the virus, leading the Philippine government to halt its national vaccination program.
In a resolution dated September 20, the CA dismissed Sanofi’s petition for review, reaffirming the permanent revocation of the CPRs.
Associate Justice Eduardo Ramos Jr. noted that the arguments presented in the motion had already been deemed without merit.
As a result, the ban on Dengvaxia remains in effect.
Source: PhilNews24 | September 26, 2024
SANOFI’S DENGVAXIA APPEAL DISMISSED BY COURT OF APPEALS
Latest from News
The national government has launched the “Bagong Bag para sa Mag-aaral” program to provide school bags
A cooperative composed of active and retired military personnel has expanded into the aviation sector with
PhilHealth said it has reached out to the family of a deceased member after a widow’s
The death toll from the recent earthquake in Mindanao has risen to 61, with 54 fatalities
The Philippine National Police (PNP) has intensified operations against scam hubs that have allegedly resurfaced as